3rd WundD.A.CH three-country congress from 29th September to 1st October 2022 in Stuttgart
64th Annual Conference of the German Society for Phlebology from 29th September to 1st October 2022 in Hannover
2022 Diabetic Lower Extremity Symposium from 3rd to 4th November in Boston, MA, USA
IWC (Interdisciplinary Wound Congress) on 24th of November 2022 in Cologne
05th Nuremberg Wound Congress from 1st to 2nd December 2022 in Nuremberg
Our daughter company RHEACELL has been granted national marketing authorization (§ 4b of the German Medicinal Products Act) in Germany for its’ cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
For the press release click here
The European Medicines Agency (EMA) has approved the pediatric investigation plan for RHEACELL´s Epidermolysis Bullosa program, bringing our daughter company one step closer to filing for marketing authorization.
Based on convincing clinical results (I/IIa) in the indication of non-healing chronic venous ulcers (CVU), RHEACELL filed for national marketing authorization in Germany (special provisions governing advanced therapy medicinal products).
Heidelberg-based biopharmaceutical company demonstrates efficacy and safety of ABCB5-positive stem cells in CVU patients in clinical phase IIa trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Heidelberg-based biopharmaceutical company successfully concludes Phase IIa clinical trial with ABCB5-positive stem cells.
Biopharma company completes three registered somatic cell therapy clinical trials for severe, chronic diseases.
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the FDA and the European Medicines Agency) and Fast Track Designation from the FDA for the treatment of LSCD.